2020-01-30| COVID-19

Update On 2019 Novel Coronavirus (2019-nCov): The Latest Progress In Vaccine Development And Treatment

by Sherry
Share To

Efforts Around the World to Develop Vaccines

Anthony Fauci, director of the US National Institute of Alliance and Infectious Diseases (NIAID), claims that they are confident to conduct a clinical phase I trial of a vaccine against the 2019-nCov in three months or less.

Johnson & Johnson has begun research on the virus and has applied its technology platform for rapid and large-scale production of optimized vaccine candidates. Meanwhile, Moderna and Inovio Pharma have announced plans to work together to develop a vaccine.

The Chinese and Russian governments are also attempting to co-develop a vaccine, and Beijing has transferred the 2019-nCoV genome data to Moscow. “Russian and Chinese experts have started developing vaccines against coronavirus,” the Russian Consulate in Guangzhou said in a statement.

Despite these accelerated developments, Novartis CEO Vas Narasimhan has shared a different view. He warned that it would take at least a year to develop an effective vaccine, and what is needed now is epidemiological control to reduce the outbreak.

Antiviral Drug

Gilead Sciences is evaluating whether its experimental RNA polymerase inhibitor remdesivir, originally developed for the treatment of Ebola, can be used against the coronavirus. Besides, AbbVie stated that it had donated USD 2 million worth HIV drug Kaletra (lopinavir / ritonavir) as an “experimental option” at the request of Chinese health authorities.

Cell Therapy

Cell therapy-related companies are not shying away from this fight either. Sorrento Therapeutics has announced a collaboration with Celularity for clinical development and manufacturing. The goal is to extend the therapeutic use of Celularity’s CYNK-001 (an allogeneic, off-the-shelf, placental-derived Natural Killer cell therapy) to treat and prevent coronavirus infections.

Related Article: Understanding the Scientific Challenges in Combating the New Coronavirus



© All rights reserved. Collaborate with us:
Related Post
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
Exciting Cell & Gene Therapy Research Updates in Glaucoma and Nerve Regeneration
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top